PT-141 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PT-141 evidence and protocol review

Signal Peptides peptide Injection solutionLyophilized research material verified

Also known as: Bremelanotide

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

1.75 mg/0.3 mL single-dose autoinjector, 10 mg research vial

Calculator

Preset available

Storage

Use source-label storage wording. Track lot, storage location, and open/reconstitution date.

Solubility

Form, salt, and formulation dependent; verify the lot-specific COA

Catalog Description

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin-4-receptor (MC4R) agonist, FDA-approved (June 21, 2019) as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Approval was based on two identical Phase 3 RECONNECT trials (Studies 301/302, 1,247 women total): participants self-administered 1.75mg bremelanotide or placebo subcutaneously at least 45 minutes before anticipated sexual activity over a 24-week randomized double-blind treatment period, with both trials showing significantly improved sexual desire and reduced related distress versus placebo and a favorable safety profile. It is one of the few compounds in this catalog with full FDA approval, and acts centrally via MC3R/MC4R, distinguishing it from peripherally acting PDE5 inhibitors.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

~2.7 hours

Onset

Dosed as-needed, ~45 minutes before anticipated sexual activity per approved label

Administration Routes (Research)

Subcutaneous (SC)

Reported Research Effects

Central MC3R/MC4R melanocortin receptor agonism
FDA-approved: increases satisfying sexual events in HSDD (two Phase 3 RCTs)
Mechanistically distinct from peripheral PDE5-inhibitor drugs

Reported Research Side Effects

Human safety, pharmacokinetics, and interaction data are incomplete

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established

Subcutaneous (SC) Label / guideline

1.75 mg at least 45 minutes before anticipated sexual activity; no more than one dose in 24 hours and eight doses per month

Frequency / timing: Label-limited
Duration / setting: As needed
Technique: SC
Evidence: Regulatory label

Context: VYLEESI prescribing information

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.

Source 1

Subcutaneous (SC) Community only

500 mcg-1.5 mg

Frequency / timing: Once daily
Duration / setting: 16 weeks
Technique: Community educational chronic SC titration
Evidence: Community-reported protocol

Context: Community educational protocol updated July 13, 2026; materially different from the FDA-approved on-demand 1.75 mg bremelanotide regimen

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from another route or product.

Route safety: Unvalidated community report. Do not treat it as a clinically established protocol or convert it to another route.

Source 1

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Notes

The approved product is bremelanotide for acquired generalized HSDD in premenopausal women. A 10 mg RUO vial is not an approved presentation.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

VYLEESI bremelanotide prescribing information — DailyMed (NIH)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf

PT-141 10 mg community dosage protocol — PeptideDosages.com
https://peptidedosages.com/single-peptide-dosages/pt-141-10-mg-vial-dosage-protocol/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.